Korro Bio (NASDAQ:KRRO) Rating Reiterated by Royal Bank of Canada

Korro Bio (NASDAQ:KRRO)‘s stock had its “outperform” rating reiterated by equities research analysts at Royal Bank of Canada in a research note issued to investors on Thursday, Benzinga reports. They presently have a $95.00 target price on the stock. Royal Bank of Canada’s price target indicates a potential upside of 161.49% from the stock’s current price.

KRRO has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Korro Bio in a research report on Tuesday. William Blair started coverage on shares of Korro Bio in a research note on Wednesday, August 14th. They set an “outperform” rating and a $180.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $135.00.

Korro Bio Price Performance

Shares of NASDAQ:KRRO opened at $36.33 on Thursday. The company’s 50-day moving average price is $43.48 and its two-hundred day moving average price is $51.22. Korro Bio has a one year low of $9.15 and a one year high of $97.91.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.04). As a group, equities analysts predict that Korro Bio will post -10.29 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Brown Brothers Harriman & Co. acquired a new position in shares of Korro Bio during the 2nd quarter worth about $28,000. Lynx1 Capital Management LP acquired a new position in Korro Bio in the 2nd quarter valued at about $129,000. Rhumbline Advisers acquired a new position in Korro Bio in the 2nd quarter valued at about $279,000. Bank of New York Mellon Corp acquired a new position in Korro Bio in the 2nd quarter valued at about $649,000. Finally, Tri Locum Partners LP acquired a new position in Korro Bio in the 2nd quarter valued at about $2,419,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).